PDS Biotechnology to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, today announced that its management will present at the Cantor Fitzgerald Virtual Global Healthcare Conference.